PRMT7 and gastric cancer: To further confirm whether PRMT7 acts via the PI3K/AKT signaling pathway, we treated siPRMT7#2-transfected cells with a PI3K/AKT inhibitor (LY294002) and then observed the proliferation, migration, and protein expression changes in GC cells.